1Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000,21(2):168-199.
2Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy(EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008,158(3):273-285.
3Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity[J]. J Clin Endocrinol Metab, 2011,96(2):320-332.
4Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?[J] Thyroid, 2012,22(1):1-2.
5Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy(EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008,18(3):333-346.
6Mourits MP, van Kempen-Harteveld ML. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study[J]. Lancet, 2000,355(9214):1505-1509.
7Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2004,89(1):15-20.
8Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2008,115(2):398-409.
9Prummel MF, Mourits MP. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy[J]. Lancet, 1993,342(8877):949-954.
10Kahaly GJ, Rosler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial[J]. J Clin Endocrinol and Metab, 2000,85(1):102-108.
